{
    "clinical_study": {
        "@rank": "68898", 
        "arm_group": {
            "arm_group_label": "HIFU hemi-ablation", 
            "arm_group_type": "Active Comparator", 
            "description": "Focal  Therapy Using  High  Intensity Focused  Ultrasound (Ablatherm)"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the rate of patients without cancer detected by biopsies performed six months\n      after hemi-ablation with high intensity focused ultrasound (HIFU) (Ablatherm \u00ae).\n\n      Evaluate the impact of the HIFU treatment on continence, sexuality and quality of life at\n      one year. Evaluate the cost of hemi-ablation HIFU treatment.\n\n      A prospective single -centre phase II, single arm, cohort study (therapeutic confirmatory)\n      offering focal therapy using HIFU (Ablatherm \u00ae) to 25 men with histologically proven\n      localised low to intermediate risk prostate cancer (PSA \u226410ng/ml, Gleason score \u2264 7 ,T1c or\n      T2b ). Precise mapping and characterisation of the disease will be established using\n      multi-parametric (mp)-MRI and prostate biopsies. Only the lobe with disease will be treated."
        }, 
        "brief_title": "Focal Therapy Using HIFU for Localised Prostate Cancer", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age\u2265 50 years\n\n          -  Clinical stage T1c (normal digital rectal examination) or T2a (one palpable nodule on\n             digital rectal examination)\n\n          -  PSA \u226410 ng / mL\n\n          -  Presence of cancer on biopsies (12 sampling biopsies  plus 2-4 targeted biopsies on\n             one side and limited to one or two contiguous areas of prostate: basic and middle or\n             middle and apex).\n\n          -  Gleason score \u2264 7 (3+4)\n\n          -  Flowmetry > 12 mL / sec for a voided volume of 125 mL\n\n          -  PVR <100 mL\n\n          -  Patient with normal anal and rectal anatomy.\n\n          -  Patient with a condition corresponding to a classification of ASA 1 or 2.\n\n          -  Patient signing ICF and agreed for following monitoring\n\n        Exclusion Criteria:\n\n          -  Patient with an ASA score 3.\n\n          -  Patient in clinical stage T1a, T1b, T2b, T2c or T3.\n\n          -  Patient with a tumor visible on MRI: Located at a distance less than 5 mm from the\n             midline. Located less than 6 mm from the apex real\n\n          -  Metastatic lymph node or metastasis discovered by MRI and bone scan.\n\n          -  Patient previously treated for his prostate cancer by hormone therapy.\n\n          -  Patient with a distance between the rectal mucosa and prostate capsule over 8 mm\n             thick\n\n          -  History of inflammatory bowel disease\n\n          -  Rectal fistula.\n\n          -  History of pelvic radiotherapy.\n\n          -  History of bladder cancer.\n\n          -  History of bladder neck sclerosis or urethral stenosis.\n\n          -  Patient with an implant located less than 1 cm from the treatment zone (stent,\n             catheter).\n\n          -  Urogenital infection.\n\n          -  Latex allergy\n\n          -  Contraindication to MRI (pacemaker,metal prosthesis ...)\n\n          -  Patient participated in another clinical study within 30 days.\n\n          -  Illiterate patients\n\n          -  Legally incapable patients"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016040", 
            "org_study_id": "#12-030"
        }, 
        "intervention": {
            "arm_group_label": "HIFU hemi-ablation", 
            "intervention_name": "High  Intensity Focused  Ultrasound", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate cancer", 
            "HIFU Hemi-ablation", 
            "Prostate biopsies"
        ], 
        "lastchanged_date": "December 13, 2013", 
        "location": {
            "contact": {
                "email": "fbladou@jgh.mcgill.ca", 
                "last_name": "Franck Bladou, MD", 
                "phone": "1-514-340-8222", 
                "phone_ext": "5166"
            }, 
            "contact_backup": {
                "email": "oloutochin@jgh.mcgill.ca", 
                "last_name": "Oleg Loutochin", 
                "phone": "1-514-340-8222", 
                "phone_ext": "1627"
            }, 
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H3T 1E2"
                }, 
                "name": "Jewish General Hospital,Urology Department"
            }, 
            "investigator": [
                {
                    "last_name": "Franck Bladou, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Maurice Anidjar, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jacques Corcos, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Focal Therapy Using High Intensity Focused Ultrasound (ABLATHERM\u00ae) for Localised Prostate Cancer", 
        "overall_contact": {
            "email": "fbladou@jgh.mcgill.ca", 
            "last_name": "Franck Bladou, MD", 
            "phone": "1-514-340-8222", 
            "phone_ext": "5166"
        }, 
        "overall_contact_backup": {
            "email": "jcorcos@jgh.mcgill.ca", 
            "last_name": "Jacques Corcos, MD", 
            "phone": "1-514-340-8222", 
            "phone_ext": "5166"
        }, 
        "overall_official": {
            "affiliation": "Jewish General Hospital,Urology Department", 
            "last_name": "Franck Bladou, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MRI,Biopsy,PSA", 
            "measure": "Rate of patients without cancer", 
            "safety_issue": "Yes", 
            "time_frame": "Six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016040"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jewish General Hospital", 
            "investigator_full_name": "Dr.Franck Bladou", 
            "investigator_title": "MD.  Professor of Oncology and Urology, McGill University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events", 
                "measure": "Immediate tolerance of hemi-ablation", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "description": "Questionnaires", 
                "measure": "Impact of the hemi-ablation HIFU treatment on continence, sexuality and quality of life", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "measure": "Cost of hemi-ablation HIFU treatment", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Jewish General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jewish General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}